David Roman, US medtech and healthcare IT research analyst for Goldman Sachs, said that AI play a 'significant' role in helping patients stay on top of their diabetes, with companies like Abbott and Dexcom using new technology to count carbohydrates and deliver the right amount of insulin. Roman, joined by Bloomberg health reporter Madison Muller, said that he came away from Goldman Sach's annual medtech conference 'very bullish' on innovation across the industry. (Source: Bloomberg)
David Roman, US medtech and healthcare IT research analyst for Goldman Sachs, said that AI play a 'significant' role in helping patients stay on top of their diabetes, with companies like Abbott and Dexcom using new technology to count carbohydrates and deliver the right amount of insulin. Roman, joined by Bloomberg health reporter Madison Muller, said that he came away from Goldman Sach's annual medtech conference 'very bullish' on innovation across the industry. (Source: Bloomberg)
Abbott Laboratories sold $20 billion of bonds to help fund its acquisition of cancer-screening company Exact Sciences Corp. on Monday, one of the US high-grade market’s biggest offerings this year.
Abbott Laboratories sold $20 billion of bonds to help fund its acquisition of cancer-screening company Exact Sciences Corp. on Monday, one of the US high-grade market’s biggest offerings this year.
A truck trailer outside the Abbott factory in Sturgis, Michigan.
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion.
In the biggest health-care deal in two years, Abbott will pay $105 per common share in cash, the companies said Thursday in a statement. The price represents a 51% premium to Exact Sciences’ closing price on Nov. 18, the last full trading day before Bloomberg reported that Abbott was nearing a deal. Bloomberg's Matt Henriksson joins to discuss with Paul
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion.
In the biggest health-care deal in two years, Abbott will pay $105 per common share in cash, the companies said Thursday in a statement. The price represents a 51% premium to Exact Sciences’ closing price on Nov. 18, the last full trading day before Bloomberg reported that Abbott was nearing a deal. Bloomberg's Matt Henriksson joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)
Abbott Laboratories has teed up the largest high-grade bridge loan this year — a $20 billion facility from Morgan Stanley — to fund its acquisition of Exact Sciences Corp.
Abbott Laboratories has teed up the largest high-grade bridge loan this year — a $20 billion facility from Morgan Stanley — to fund its acquisition of Exact Sciences Corp.
An Abbott Nutrition distribution center in Columbus, Ohio, US, on Sunday, July 28, 2024. Abbott Laboratories is considering pulling infant formula for premature babies off the market, Chief Executive Officer Robert Ford said, amid investor concerns about lawsuits over its safety.
Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the global health-care sector.
Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the global health-care sector.
Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the global health-care sector.
Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the global health-care sector.
Anmelden
